Tag: activities

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

Bold Partner-led strategies continue to build momentum and produce all-time highs in Activation and Premium Memberships revenue

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- CoinBom has officially launched its new AI-Powered Copy Trading System, marking a significant milestone in the platform’s continued commitment to intelligent wealth management and quantitative investment. This system integrates advanced AI algorithms with cyclical trading strategies, offering users a more stable and efficient way to grow their digital asset portfolios.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SkyCrest Capital, a global fintech innovator, today announced the launch of its transformative Pension Plan, a structured asset growth initiative set to begin on Monday, June 23, 2025. Powered by the proprietary SAX-iCore AI Structural Recognition System and executed via the LEXO decentralized trading platform, the plan targets a 150% net return in its first week, offering individual traders and investors a disciplined, AI-driven path to wealth accumulation.

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2

WOODLAND PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced fiscal 2025 fourth quarter and full fiscal year financial results and filed its 10-K for the year ended March 31, 2025. The Company also issued an update on its Demonstrated Intent metric which can be found on Anterix’s website at https://investors.anterix.com/events-presentations.